<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04801472</url>
  </required_header>
  <id_info>
    <org_study_id>2020-013</org_study_id>
    <nct_id>NCT04801472</nct_id>
  </id_info>
  <brief_title>Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM)</brief_title>
  <acronym>OPPIDOM</acronym>
  <official_title>Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de cancérologie Strasbourg Europe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hôpitaux Universitaires de Strasbourg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de cancérologie Strasbourg Europe</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a monocentric, non-randomized, prospective, in silico feasibility study conducted by&#xD;
      Strasbourg Europe Cancerology Institute. The purpose of this study is to evaluate the&#xD;
      optimisation of potential dental implant sites protection, without degrading tumor volume&#xD;
      coverage, through designation of potential dental implant sites before volume delineation and&#xD;
      dosimetry calculations in patients with oropharyngeal or oral cavity squamous cell carcinoma&#xD;
      treated by radiotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      30 patients will be included in this study and will benefit from a dental consultation for&#xD;
      dental rehabilitation plan elaboration and radiological guide confection. Two dosimetric&#xD;
      computer-tomography scans, with or without radiological guide, will be conducted. Virtual&#xD;
      dental implants will be visualised by the dental surgeon on scanner images (with or without&#xD;
      radiologic guide). After volume delineation and dosimetry calculations, the optimal treatment&#xD;
      plan will be validated. Patients will be followed throughout radiotherapy and during 18&#xD;
      months following the end of radiotherapy for evaluation of toxicity, quality of life and&#xD;
      dental implant survival rate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of optimal scanner allowing to obtain the greater number of patients with every designated implant sites that are protected</measure>
    <time_frame>At baseline</time_frame>
    <description>Condition of dental implant sites protection (i.e. with minimal implantation risk, Dmax &lt; 40 Gy), without degrading the coverage of planned targeted volume (≥ 95% of volume receiving 95 % of prescribed dose)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity evaluation</measure>
    <time_frame>every weeks during radiotherapy</time_frame>
    <description>according to CTCAE v5.0 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retarded toxicity evaluation</measure>
    <time_frame>3 months, 6 months, 12 months, 18 months after the end of radiotherapy</time_frame>
    <description>according to CTCAE v5.0 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by the EORTC QLQ-C30 questionnaire</measure>
    <time_frame>At baseline, every weeks during radiotherapy and at 3 months, 6 months, 12 months, 18 months after the end of radiotherapy</time_frame>
    <description>Score based on 30 items from EORTC QLQ-C30 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life for patient with Head and Neck Cancer assessed by the EORTC QLQ-H&amp;N35 supplementary questionnaire module</measure>
    <time_frame>At baseline, every weeks during radiotherapy and at 3 months, 6 months, 12 months, 18 months after the end of radiotherapy</time_frame>
    <description>Score based on 35 items from EORTC QLQ-H&amp;N35 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral health-related impact on patients quality of life assessed by the OHIP-14 questionnaire</measure>
    <time_frame>At baseline, every weeks during radiotherapy and at 3 months, 6 months, 12 months, 18 months after the end of radiotherapy</time_frame>
    <description>Score based on 14 items from OHIP-14 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implant survival rate</measure>
    <time_frame>at 3 months, 6 months, 12 months, 18 months after the end of radiotherapy</time_frame>
    <description>Number of implant failure (Albrektsson modified criteria)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Squamous Cell Carcinoma of Head and Neck</condition>
  <condition>Oropharyngeal Squamous Cell Carcinoma</condition>
  <condition>Oral Cavity Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Patients with oral cavity or oropharyngeal squamous cell carcinoma</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Optimisation of dental implant sites protection from irradiation</intervention_name>
    <description>Optimal treatment plan validation after two dosimetric computer-tomography scans (with or without radiological guide) and visualisation of virtual dental implants on scanner images.&#xD;
Evaluation of toxicity, quality of life and dental implant survival rate</description>
    <arm_group_label>Patients with oral cavity or oropharyngeal squamous cell carcinoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be ≥ 18 years old&#xD;
&#xD;
          -  Performance Status 0 to 2&#xD;
&#xD;
          -  Histologically-confirmed diagnosis of : infiltrating squamous cell carcinoma of the&#xD;
             oral cavity or oropharynx&#xD;
&#xD;
          -  Indication for an exclusive radiotherapy or post-surgery radiotherapy, with or without&#xD;
             chemotherapy&#xD;
&#xD;
          -  Indication for a radiotherapy of lymph node areas&#xD;
&#xD;
          -  Partial or complete toothlessness requiring rehabilitation&#xD;
&#xD;
          -  Signed informed consent from the patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of head and neck radiotherapy&#xD;
&#xD;
          -  Partial mandibulectomy&#xD;
&#xD;
          -  Retarded wound healing impairing radiological guide preparation&#xD;
&#xD;
          -  Patient refusing the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Valérie SARTORI</last_name>
    <phone>368767223</phone>
    <phone_ext>33</phone_ext>
    <email>v.sartori@icans.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manon VOEGELIN, PhD</last_name>
    <phone>368767360</phone>
    <phone_ext>33</phone_ext>
    <email>promotion-rc@icans.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de cancérologie Strasbourg Europe</name>
      <address>
        <city>Strasbourg</city>
        <zip>67033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie SARTORI</last_name>
      <phone>368767223</phone>
      <phone_ext>33</phone_ext>
      <email>v.sartori@icans.eu</email>
    </contact>
    <contact_backup>
      <last_name>Manon VOEGELIN</last_name>
      <phone>368767360</phone>
      <phone_ext>33</phone_ext>
      <email>m.voegelin@icans.eu</email>
    </contact_backup>
    <investigator>
      <last_name>Georges NOEL, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabien BORNERT, Dental Surgeon</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Youssef BRAHIMI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Minh-Nhat NGUYEN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2021</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radiotherapy</keyword>
  <keyword>Head and Neck cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

